A prospective feasibility study of one-year administration of adjuvant S-1 therapy for resected biliary tract cancer in a multi-institutional trial (Tokyo Study Group for Biliary Cancer: TOSBIC01) | BMC Cancer | Full Text

A prospective feasibility study of one-year administration of adjuvant S-1 therapy for resected biliary tract cancer in a multi-institutional trial (Tokyo Study Group for Biliary Cancer: TOSBIC01) | BMC Cancer | Full Text

A prospective feasibility study of one-year administration of adjuvant S-1 therapy for resected biliary tract cancer in a multi-institutional trial (Tokyo Study Group for Biliary Cancer: TOSBIC01)

Although surgery is the definitive curative treatment for biliary tract cancer (BTC), outcomes after surgery alone have not been satisfactory. Adjuvant therapy with S-1 may improve survival in patients with BT...

Authors:Osamu Itano, Yusuke Takemura, Norihiro Kishida, Eiji Tamagawa, Hiroharu Shinozaki, Ken Ikeda, Hidejiro Urakami, Shigenori Ei, Shigeo Hayatsu, Keiichi Suzuki, Tadayuki Sakuragawa, Masatsugu Ishii, Masaya Shito, Koichi Aiura, Hiroto Fujisaki, Kiminori Takano…

Citation:BMC Cancer 2020 20:688

Content type:Research article

 

Published on: 23 July 2020

• ViewFull Text
 
• ViewPDF